Tom Powles, Professor at the University of London, shared a post on X:
“Here is a podcast with Neal Shore around the CREST RIII untreated NMIBC BCG +/- PD1 trial which show and EFS advantage but with expected immune related toxicity.
Here we discuss the highlights and risk benefit ratio.”
More posts featuring Tom Powles.